Literature DB >> 27207509

Insulin-Dependent Regulation of mTORC2-Akt-FoxO Suppresses TLR4 Signaling in Human Leukocytes: Relevance to Type 2 Diabetes.

Zhiyong Zhang1, Louis F Amorosa2, Susette M Coyle1, Marie A Macor1, Morris J Birnbaum3, Leonard Y Lee1, Beatrice Haimovich4.   

Abstract

Leukocyte signaling in patients with systemic insulin resistance is largely unexplored. We recently discovered the presence of multiple Toll-like receptor 4 (TLR4) signaling intermediates in leukocytes from patients with type 2 diabetes or acute insulin resistance associated with cardiopulmonary bypass surgery. We extend this work to show that in addition to matrix metalloproteinase 9, hypoxia-inducible factor 1α, and cleaved AMPKα, patient leukocytes also express IRS-1 phosphorylated on Ser(312), Akt phosphorylated on Thr(308), and elevated TLR4 expression. Similar signaling intermediates were detected in leukocytes and neutrophils treated with lipopolysaccharide (LPS), a ligand of TLR4, in vitro. In contrast, insulin, but not LPS, induced mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt on Ser(473) and FoxO1/O3a on Thr(24/32) in leukocytes and neutrophils. Insulin suppressed LPS-induced responses in a dose- and time-dependent manner. AS1842856, a FoxO1 inhibitor, also suppressed TLR4 signaling. We propose that insulin is a homeostatic regulator of leukocyte responses to LPS/TLR4 and that the signaling intermediates expressed in leukocytes of patients with type 2 diabetes indicate TLR4 signaling dominance and deficient insulin signaling. The data suggest that insulin suppresses LPS/TLR4 signals in leukocytes through the mTORC2-Akt-FoxO signaling axis. Better understanding of leukocyte signaling in patients with type 2 diabetes may shed new light on disease causation and progression.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27207509     DOI: 10.2337/db16-0027

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

Review 1.  The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy.

Authors:  Seyed Hossein Aghamiri; Khalil Komlakh; Mehran Ghaffari
Journal:  Inflammopharmacology       Date:  2022-01-12       Impact factor: 4.473

2.  Insulin Receptor Genetic Variants Causal Association with Type 2 Diabetes: A Mendelian Randomization Study.

Authors:  Ghada A Soliman; C Mary Schooling
Journal:  Curr Dev Nutr       Date:  2022-03-29

3.  Obesity and Type 2 Diabetes mellitus induce lipopolysaccharide tolerance in rat neutrophils.

Authors:  Wilson Mitsuo Tatagiba Kuwabara; Caroline Naomi Fukusawa Yokota; Rui Curi; Tatiana Carolina Alba-Loureiro
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

4.  Shared Causal Paths underlying Alzheimer's dementia and Type 2 Diabetes.

Authors:  Zixin Hu; Rong Jiao; Panpan Wang; Yun Zhu; Jinying Zhao; Phil De Jager; David A Bennett; Li Jin; Momiao Xiong
Journal:  Sci Rep       Date:  2020-03-05       Impact factor: 4.379

5.  Carrageenan-Free Diet Shows Improved Glucose Tolerance and Insulin Signaling in Prediabetes: A Randomized, Pilot Clinical Trial.

Authors:  Leo Feferman; Sumit Bhattacharyya; Erin Oates; Nicole Haggerty; Tianxiu Wang; Krista Varady; Joanne K Tobacman
Journal:  J Diabetes Res       Date:  2020-04-21       Impact factor: 4.011

6.  Metformin Reduces Lipotoxicity-Induced Meta-Inflammation in β-Cells through the Activation of GPR40-PLC-IP3 Pathway.

Authors:  Ximei Shen; Beibei Fan; Xin Hu; Liufen Luo; Yuanli Yan; Liyong Yang
Journal:  J Diabetes Res       Date:  2019-12-18       Impact factor: 4.011

Review 7.  The regulatory role of insulin in energy metabolism and leukocyte functions.

Authors:  Walter David Cruz-Pineda; Isela Parra-Rojas; Hugo Alberto Rodríguez-Ruíz; Berenice Illades-Aguiar; Inés Matia-García; Olga Lilia Garibay-Cerdenares
Journal:  J Leukoc Biol       Date:  2021-03-16       Impact factor: 6.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.